Photo credit: Image courtesy of Abdullah Metebi, PhD student at the Institute for Quantitative Health Science and Engineering, Michigan State University.
Reston, VA (Embargoed until 11:00 a.m. EDT, Friday, June 11, 2021) – Preclinical studies of a new radiopharmaceutical to treat ovarian cancer have produced successful results that drastically limit tumor growth and reduce tumor mass. Specially developed for ovarian cancers that are resistant to conventional therapies, the new radiopharmaceutical can be manufactured inexpensively in 25 minutes, resulting in better efficiency compared to alternative methods. This research was presented at the Society for Nuclear Medicine and Molecular Imaging at the 2021 annual meeting.
According to the American Cancer Society, more than 20,000 women are diagnosed with ovarian cancer each year and nearly 14,000 will die from the disease. Ovarian cancer patients have a 5-year survival rate of 49.1 percent. It is the fifth leading cause of cancer-related death in women.
In the study, the researchers used a new generator system to develop the targeted alpha therapy Pb-214-TCMC-trastuzumab for the treatment of HER2-positive ovarian cancer. Ovarian cancer cells and mice with ovarian cancer tumors were divided into three groups: those treated with Pb-214-TCMC-trastuzumab, those treated with Pb-214-TCMC-IgG, and an untreated control group. All groups were mapped over time to determine treatment effectiveness.
Compared to the Pb-214-TCMC-IgG and control groups, the tumor signal in mice and cells treated with Pb-214-TCMC-trastuzumab decreased dramatically over the course of the study, which signals the effectiveness of the therapy. There were no adverse treatment side effects as determined by the weight loss of all surviving animals.
“Pb-214’s short half-life of 27 minutes is ideal for therapeutic applications involving fractionated alpha particles,” said Mike Zamiara, study author and president of Niowave Inc. in East Lansing, Michigan. “The generator system can deliver Pb-214 every hour, potentially offering patients a new source of alpha particle therapy at a lower cost. In the future, the generator system for many therapeutic products will be available in a turnkey system under development and will deliver reliable dosages for improved patient care. ”
Abstract 93. “Therapeutic efficacy of Pb-214-labeled trastuzumab in a preclinical model of ovarian cancer,” Abdullah Metebi, Comparative Medicine and Integrative Biology, Michigan State University, East Lansing, Michigan; Chelsea Nayback, Institute of Quantitative Health Science and Technology, Michigan State University, East Lansing, Michigan; Jinda Fan, Departments of Radiology and Chemistry, Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan; Nathan Johnson, John Diemer, Terry Grimm, Mike Zamiara, Niowave, Inc., Lansing, Michigan; and Kurt Zinn, Radiology and Quantitative Health Science and Technology Institute, Michigan State University, East Lansing, Michigan.
All abstracts of the SNMMI annual conference 2021 can be found online at https: /
About the Society for Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging results.
SNMMI members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings, and advocating key issues affecting the research and practice of molecular imaging and therapy. Further information is available at http: // www.